AI CuratorAI-generated
Research summary · AI summary · not yet reviewedSubjects not reportedNot reportedPeer review unconfirmed
Viable S1P Release Inhibitors: Compounds 6c and 6k
Compounds 6c and 6k were identified as viable inhibitors of S1P release with IC50 values of 651 ± 3 nM and 719 ± 50 nM, respectively. Molecular modeling indicated that conformational effects can influence their potency.
- Most relevant to
- Neurologist, Pharmacologist
This plain-English summary was written by AI from a published abstract and may contain errors. It is not medical advice. Read the original study and talk to your MS team before making decisions about treatment.
Why it matters
These findings contribute to the understanding of S1P release inhibition, which could be relevant for future drug development, particularly in conditions like multiple sclerosis.
What this does not prove
This study does not establish clinical efficacy in multiple sclerosis or any specified human MS subtype.
Next milestone
No next milestone was established from the available source.
Study facts
- Study design
- Not reported
- Participants / samples
- Not reported
- Randomised
- Not reported
- Controlled
- Not reported
- Primary endpoint met
- Not reported
- Relevant MS type
- Not reported
- Publication date
- 2026-09-26
- Evidence reviewed
- Abstract only
- Regulatory approval
- Not reported
- Research areas
- Not classified
Original sources
- Primary evidenceNew Indazole Compounds Show Promise as S1P Release Inhibitors ↗
Supporting passages (3)
publication datePublication date: 2026-09-26
findingsStudies revealed compounds 6c (IC50 = 651 ± 3 nM) and 6k (IC50 = 719 ± 50 nM) to be viable SRIs with molecular modeling suggesting that conformational effects are observed and potency can be influenced by these effects.
limitationsTitle: Structure-activity profiling of indazole-based derivatives as spinster homolog 2 (Spns2)-dependent S1P release inhibitors.
AI assessment, not yet reviewed by a person · version 1 · Community votes are separate from evidence review.